Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:1.6.99.1 (
NADPH-diaphorase
)
3,903
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Nitric oxide has been proposed to play an important role in neuronal development. We have previously shown that growth cones from an identified neuron, B5, in the snail Helisoma trivolvis, respond to nitric oxide (NO) donors by increasing the length of their filopodia within minutes of application (Van Wagenen and Rehder, 1999). This effect was mediated through a cGMP-induced increase in [Ca2+]i and resulted in an enlargement of the growth cone's action radius, suggesting that NO could function as a signaling molecule during neuronal pathfinding. We show here that NO functions as a specific rather than a general regulator of growth cone filopodia, because another identified neuron from the same ganglion,
B19
, failed to respond to NO with an increase in filopodial length. We found that, contrary to B5 neurons,
B19
growth cones contained little or no soluble guanylyl cyclase (sGC) immunoreactivity, presumably preventing their response to NO. This hypothesis was supported by the finding that the sGC activator YC-1 (10 microM) had no effect on
B19
filopodia but induced elongation of B5 filopodia. These results indicate that the effects of NO can be quite specific, and raise the interesting possibility that neurons could selectively tune in to NO by differentially expressing the target enzyme sGC in the appropriate cellular location during critical developmental stages. In addition, our
NADPH-diaphorase
staining and anti-NOS immunohistochemisty suggest that growth cones of B5 neurons, but not of
B19
neurons, could be a source of NO, making NO a potential intra- and transcellular messenger.
...
PMID:Regulation of neuronal growth cone filopodia by nitric oxide depends on soluble guanylyl cyclase. 1116 6